Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from HUTCHMED (China) ( (HK:0013) ).
HUTCHMED (China) Limited announced that it will present new and updated clinical data from its studies at the 2025 World Conference on Lung Cancer and the CSCO Annual Meeting. The presentations will include data on savolitinib, a MET tyrosine kinase inhibitor developed with AstraZeneca, and HMPL-653, a CSF-1R inhibitor, among others. These presentations underscore HUTCHMED’s ongoing commitment to advancing cancer treatment and highlight its strategic collaborations and innovative pipeline, potentially enhancing its position in the oncology market.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates primarily in the oncology sector and collaborates with global pharmaceutical companies like AstraZeneca to advance its drug candidates.
Average Trading Volume: 11,379,036
Technical Sentiment Signal: Hold
Current Market Cap: HK$21.21B
Learn more about 0013 stock on TipRanks’ Stock Analysis page.